Skip to content

Role of Clinical Pharmacists in Epilepsy Management

Role of Clinical Pharmacists in Epilepsy Management at a General Hospital in Vietnam: A Before-and-after Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04967326
Enrollment
141
Registered
2021-07-19
Start date
2016-01-01
Completion date
2018-12-31
Last updated
2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

epilepsy, role of pharmacist, adverse drug reaction, antiepileptic drug, Vietnam

Brief summary

Clinical pharmacists have an important role in inter-professional healthcare collaboration for epilepsy management. However, the pharmacy practices of managing epilepsy are still limited in Vietnam, deterring pharmacists from routine adjustments of antiepileptic drugs, which could decrease the patients' quality of life. This study aimed to assess the effectiveness of pharmacist interventions in epilepsy treatment at a Vietnamese general hospital.

Detailed description

Phenytoin, carbamazepine, and valproic acid, which are among the first-generation AEDs, are prescribed in many countries around the world, including Vietnam. These agents have complicated pharmacokinetics, which may result in alterations in absorption, distribution, and metabolism. This means that, given the same dose, the serum concentration of each drug may vary between patients. The management of epilepsy, as a result, requires inter-professional collaboration to ensure therapeutic optimization. As healthcare professionals, clinical pharmacists play an important role in epilepsy management, which includes establishing a therapeutic drug monitoring (TDM) protocol, adjusting doses, monitoring ADRs, etc. However, the clinical pharmacy practices in epilepsy management are quite limited in Vietnam. The treatment gap-the proportion of people with epilepsy who are not adequately treated-still remains very high, especially in rural areas (84.7%), which probably results from discontinuing the treatment or refusing to take medications. This shows a need for pharmacist consultations for patients with epilepsy and their family members, as they may be lack information about AEDs or motivation in controlling potential seizures. In addition, the adjustments of antiepileptic drugs by pharmacists are not routine procedures, nor are monitored for effectiveness in many Vietnamese hospitals. This lack of engagement threatens the patients' safety and decreases their quality of life. To address this issue, certain interventions are needed to enable pharmacists to manage patients with epilepsy more systematically. This study was therefore conducted to evaluate the effectiveness of pharmacist interventions in epilepsy treatment at a general hospital in Vietnam.

Interventions

DRUGOptimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)

Sponsors

Gia Dinh People Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* were prescribed a monotherapy or polytherapy of phenytoin, carbamazepine, or valproic acid. * were treated for more than one month.

Exclusion criteria

* were pregnant or breastfeeding women. * had a history of alcoholism. * had liver or renal disease. * were using drugs known to have an influence on cytochrome P450 enzymes.

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with two seizures or lessOne year from the start of the studyPatients with two seizures or less in a year were categorized as having good control, whereas those who had more were considered to have poor control.

Secondary

MeasureTime frameDescription
Number of patients who maintained an optimized concentration of antiepileptic drugsOne year from the start of the studyThe targeted therapeutic ranges for carbamazepine, phenytoin, and valproic acid were 4-12 mg/L, 10-20 mg/L, and 50-100 mg/L, respectively.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026